Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29

RefinitivMenos de 1 minuto de leitura

Immuneering Corp IMRX:

IMMUNEERING TO DISCUSS RECENTLY ANNOUNCED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON MONDAY, SEPTEMBER 29, 2025

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Entrar ou criar uma conta gratuita para ler essa notícia